SUBSCRIBE
SUBSCRIBE
News   Drug Development

Biogen Idec, Inc. (Massachusetts) (JOBS), Elan Corporation PLC (JOBS) Shares Plummet on New Tysabri Review

October 23, 2009 | 
1 min read
Bookmark and Share

Reuters -- European regulators said they have begun a review of the multiple sclerosis drug Tysabri following reports of 23 cases of a potentially deadly brain infection.
Clinical research Postmarket research
Biogen
MORE ON THIS TOPIC
Podcast
Pfizer Wins Metsera, Trump Strikes GLP-1 Pricing Deal, FDA Awards More Priority Vouchers
November 12, 2025
 · 
1 min read
 · 
Heather McKenzie
3d rendering medical heart in yellow background
Cardiovascular disease
Amgen, Merck, Novo, More Take Cardiovascular Benefits to New Heights at AHA 2025
November 11, 2025
 · 
5 min read
 · 
Tristan Manalac
Unhappy young woman feel lonely abandoned in crowd suffer from communication lack. Upset girl struggle with depression or mental disorder. Psychological problem. Flat vector illustration.
Depression
Neurocrine’s Depression Drug Delivers ‘Surprise’ Phase II Miss
November 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Changing or transforming, turning around, challenging the odds and conquering adversity, a businessman pole vaulting from the down arrow to the up arrow of growth
Cancer
Cogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDA
November 11, 2025
 · 
2 min read
 · 
Tristan Manalac